My Fund

Loading your portfolio…

Checking your account and saved picks.

Choose a startup

Explore all 1429 companies in this selection. Research each company before making your pick.

Includes historical VC holdings. A listing does not confirm current ownership or startup stage.

VC tracking →

Showing 1–1 of 1 startup

Tempest Therapeutics, Inc.

Limited coverage

Biotechnology

On its website, the company describes its work as “About Tempest Therapeutics Developing differentiated solutions for the next generation of in vivo CAR-T therapies Tempest Therapeutics is a clinical-stage biotechnology company focused on pioneering…”.

No tracked VC backing recorded
tempesttx.com ↗
Research Tempest Therapeutics, Inc.

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Limited coverage
Verified filings recorded. Existing baseline history earns no points.SEC source checked:
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

What it does

On its website, the company describes its work as “About Tempest Therapeutics Developing differentiated solutions for the next generation of in vivo CAR-T therapies Tempest Therapeutics is a clinical-stage biotechnology company focused on pioneering…”.

Visit tempesttx.com ↗Product description source ↗

Tracked VC backing

No tracked VC backing recorded.

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

  • · Form D filing · Baseline

    Reported sold as filed: $7,500,000 · Offering amount as filed: $7,500,000

    SEC source checked 29 Oct 2026. Historical filing, not a current valuation.

    View original evidence ↗

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗
How it works

Pick up to 50 companies. Your picks are private to your account.

A new US fundraising disclosure (Form D) earns 2 points. A first investment announced by a tracked VC earns 3. Milestones must occur and be observed after your pick.

Measured growth earns 1 point once: the same RiseFinder composite score rises between dated observations after your pick, using one formula version. Where available, a supported public source metric can also qualify. Lower ranks are better; rising counts are better. A completed, dated IPO or acquisition earns 10 points once.

The composite score measures relative public signals on a 0–100 scale. It is not a company valuation. Coverage varies; companies without qualifying history wait for evidence.

Initial imports, old discoveries, follow-ons from existing backers, amendments, undated events and same-day events earn no points.

Points track verified milestones after your pick. They do not represent investment returns.